Septerna, Inc.

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs). Its lead program is the PTH1R Program, which aims to develop oral small molecule Parathyroid Hormone 1 Receptor agonists for treating hypoparathyroidism. The company also has SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and mast cell diseases, and a TSHR Program developing an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. Additionally, Septerna is exploring other therapeutic areas including neurology, women's health, cardiovascular disease, and respiratory disease. The company has a global collaboration with Novo Nordisk to discover and commercialize oral small molecule therapies for metabolic-related diseases.

Septerna, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol SEPN. The company's stock is traded in United States Dollars (USD). As a US-based company listed on a major US exchange, its shares are accessible to investors through standard brokerage accounts, and all financial reporting is conducted in USD.

Septerna operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative therapies for diseases with significant unmet medical needs. Its work involves leveraging GPCR biology to create oral small molecule drugs, which are designed to be more convenient for patients compared to injectable biologics. The company's pipeline targets endocrinology, immunology and inflammation, and metabolic diseases, reflecting its broad therapeutic focus within the biotech space.

Septerna, Inc. is headquartered in South San Francisco, California, United States. The company was incorporated in 2019 and was originally known as GPCR NewCo, Inc. before rebranding to Septerna in June 2021. While its primary operations are based in the US, its collaboration with Novo Nordisk, a global healthcare company, indicates an international reach for its metabolic disease programs. The company's therapies are intended for patients worldwide, particularly those suffering from hypoparathyroidism, chronic spontaneous urticaria, Graves' disease, and other conditions.

Septerna is a clinical-stage biotechnology company that currently does not have any approved products on the market, so it does not generate revenue from product sales. Instead, its business model involves advancing its pipeline of oral small molecule GPCR-targeted therapies through preclinical and clinical development. The company generates revenue through collaborations and licensing agreements, such as its global collaboration with Novo Nordisk to discover and commercialize oral small molecule therapies for metabolic diseases. Under such agreements, Septerna may receive upfront payments, milestone payments, and royalties on future product sales. The company also relies on equity financing and partnerships to fund its research and development activities.